Investigating Neuroimaging Endophenotypes for Autism Spectrum Disorder
1 other identifier
observational
90
1 country
1
Brief Summary
Specific Aims: This study aims to examine the hypothesis that individuals with Autism spectrum disorder (ASD) and their unaffected siblings shared alterations in gray and white matter volume and their associated intrinsic functional connectivity, to build upon limited literature about neuroimaging endophenotypes of ASD. The investigators also aim to test whether these shared differences are associated with behavioral autistic traits.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
March 22, 2016
CompletedFirst Posted
Study publicly available on registry
March 28, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2016
CompletedSeptember 2, 2021
September 1, 2021
1 year
March 22, 2016
September 1, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Psychiatric Interview
Subjects will be interviewed by Chinese Version of the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E)
1 hour
Study Arms (3)
ASD group
Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
Sibling group
Sex-matched unaffected siblings of ASD probands
TD group
Typically developing controls without lifetime ASD or a family history of ASD
Eligibility Criteria
The sample consists of 30 adults with ASD, and 30 sex-matched unaffected siblings, and 30 healthy volunteers.
You may qualify if:
- \. Subjects who have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
You may not qualify if:
- Systemic medical illness
- Current symptoms or lifetime history of DSM-5 diagnosis of mood disorder, any psychotic disorder, substance use disorder, learning disorder, anxiety disorder, claustrophobia, obsessive compulsive disorder, or mental retardation.
- With neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy;
- Full-scale IQ \< 70.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan Univeristy Hospital
Taipei, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hsiang-Yuan Lin, MD
Dept of Psychiatry, National Taiwan University Hospital
- STUDY DIRECTOR
Susan Shur-Fen Gau, MD, PhD
National Taiwan University Hospital & College of Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 22, 2016
First Posted
March 28, 2016
Study Start
January 1, 2016
Primary Completion
December 31, 2016
Study Completion
December 31, 2016
Last Updated
September 2, 2021
Record last verified: 2021-09